Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2021 on request of the Sponsor.
On 4 July 2014, orphan designation (EU/3/14/1289) was granted by the European Commission to A1M Pharma AB, Sweden, for recombinant human alpha-1-microglobulin for the treatment of pre‑eclampsia.
In April 2021, A1M Pharma AB changed name to Guard Therapeutics International AB.
Recombinant human alpha-1-microglobulin
Treatment of pre-eclampsia
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: